Neurotherapeutics Group

Our group has expertise in medicinal chemistry (in association with Prana Biotechnology) and in biomarker discovery. We focus on the pathways leading to Parkinson’s disease, especially around the oxidative modifications of tau.

The Australian Imaging, Biomarker and Lifestyle (AIBL) Study, the Dementia Collaborative Research Centres (DCRC) and the Cooperative Research Centre for Mental Health (CRCMH) are intimately involved in our research programs, relying on patient cohorts for biomarker and imaging discovery in both neurodegenerative and psychotic illness.

Research interests

  • Parkinson’s disease
  • Alzheimer’s disease
  • NMDA receptors

Research team

Research team head

Research and technical staff

  • Xiang Liu



  • Beauchamp, L.C., Liu, X.M., Vella, L.J., Adlard, P.A., Bush, A.I., Finkelstein, D.I. and Barnham, K.J. (2022). ATH434 Rescues Pre-motor Hyposmia in a Mouse Model of Parkinsonism. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics, [online] 19(6), pp.1966–1975. doi:
  • Beauchamp, L.C., Finkelstein, D.I., Bush, A.I., Evans, A.H. and Barnham, K.J. (2020). Parkinsonism as a Third Wave of the COVID-19 Pandemic? Journal of Parkinson’s Disease, 10(4), pp.1343–1353. doi:
  • McKenzie-Nickson, S., Chan, J., Perez, K., Hung, L.W., Cheng, L., Sedjahtera, A., Gunawan, L., Adlard, P.A., Hayne, D.J., McInnes, L.E., Donnelly, P.S., Finkelstein, D.I., Hill, A.F. and Barnham, K.J. (2018). Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies. ACS chemical neuroscience, [online] 9(11), pp.2731–2740. doi:

Contact us

Professor Kevin Barnham

Group Head
[email protected]